SCHEMBL63534

SCHEMBL63534

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCc2cccs2)c(O)c1=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.40
CYP2C9 P11712 1/20 0.38
ALDH1A1 P00352 6/20 0.36
TSHR P16473 4/20 0.36
KDM4E B2RXH2 2/20 0.36
RAB9A P51151 4/20 0.35
KMT2A Q03164 5/20 0.35
NPC1 O15118 3/20 0.35
HPGD P15428 3/20 0.35
MEN1 O00255 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PKM P14618 2/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TAS2R8 Q9NYW2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63906 0.92 ERCC1 (0.36) CYP2C9ALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL53142 0.87 CYP2C9 (0.45) HTTCYP2C9ALDH1A1KDM4ERAB9A
SCHEMBL64543 0.86 CYP2C9 (0.45) HTTCYP2C9ALDH1A1TSHRKDM4E
SCHEMBL64267 0.86 ALDH1A1 (0.40) HTTCYP2C9ALDH1A1TSHRKDM4E
SCHEMBL64597 0.85 CYP2C9 (0.47) CYP2C9
SCHEMBL64282 0.85 CYP2C9 (0.39) HTTCYP2C9ALDH1A1HPGDSMN1; SMN2
SCHEMBL64262 0.85 HPGD (0.39) CYP2C9RAB9ANPC1HPGD
SCHEMBL63518 0.85 CYP2C9 (0.46) HTTCYP2C9ALDH1A1KDM4ERAB9A
SCHEMBL64544 0.84 CYP2C9 (0.41) CYP2C9ALDH1A1KDM4EKMT2AHPGD
SCHEMBL62564 0.84 CYP2C9 (0.38) HTTCYP2C9ALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG HTT 4616/4885CYP2C9 602/4885ALDH1A1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.